Novo Nordisk (NVO.US) Testing Ozempic for Alzheimer's Disease with Trial Results Expected This Fall

From obesity and diabetes to heart disease and liver disease, the applications of GLP-1 drugs like Ozempic (semaglutide) have continued to expand since its introduction seven years ago. Now, Novo Nordisk (NVO.US) is testing the drug's effects on Alzheimer’s disease.

A Few Years Ago, a Team of Scientists Discovered Something Surprising While Studying Danish Health Registry Data: Diabetic Patients Using Novo Nordisk's Previous Generation Diabetes Drug, Victoza, or Similar GLP-1 Drugs, Had a Significantly Lower Incidence of Dementia Compared to Those Using Other Treatments. Specifically, Adults Who Continuously Injected the Drug for Two Years Saw Their Risk of Being Diagnosed with Dementia Reduced by Approximately 20%.

Novo Nordisk Chief Science Officer Martin Holst Lange stated, "This in itself cannot serve as conclusive evidence, but it certainly caught our attention." At the time, Novo Nordisk was already investigating whether its updated GLP-1 drugs could help patients with obesity-related heart, liver, and joint diseases. Motivated by this Danish data analysis (which Novo Nordisk also participated in publishing), the company decided to simultaneously test the efficacy of these drugs on Alzheimer's disease.

These clinical trial results are expected to be released this fall. If everything goes as Novo Nordisk hopes, GLP-1 drugs could revolutionize the treatment of Alzheimer's disease. While success is far from guaranteed, the potential payoff would be enormous. Analysts at UBS estimate that there is a 1-in-10 chance the company could gain an additional $15 billion in annual sales in the Alzheimer’s market. "We are excited about it, but we also see the risks as very high," said Martin Holst Lange.

Novo Nordisk Plans to Release Data from Two Ozempic Trials Involving More Than 3,500 Patients with Mild Alzheimer's at a Conference in San Diego Early December.If industry惯例 are followed, the company may announce whether the trial succeeded or failed earlier after the data analysis is completed.

Current Alzheimer's drugs mainly work by targeting amyloid proteins, which are toxic misfolded proteins that accumulate in patients' brains. However, the approach with semaglutide is different. The drug mimics a gut hormone called GLP-1, which researchers believe may work by reducing inflammation and altering how the brain uses sugar. Multiple studies have shown that people with diabetes are more likely to develop dementia, so this connection may be reasonable.